Abstract
Aim. To assess levels of interleukin-6 (IL-6) and cardial infarction patients receiving clopidogrel or ticaC-reactive protein (CRP) in ST-segment elevation myogrelor in the in-hospital period. Methods. 80 patients with STEMI were included in the study. All patients received a loading dose of aspirin (250 mg) and clopidogrel (600 mg) in the ambulance. All patients underwent urgent coronary angiography with the further stenting of the infarct-related artery with bare-metal stents. All patients were assigned to two groups using simple random sampling. Group 1 patients received a daily maintenance dose of clopidogrel 75 mg. Group 2 patients received a maintenance dose of ticagrelor 90 mg twice daily. Plasma levels of IL-6 and CRP were measured on day 1 after the hospital admission before replacing clopidogrel to ticagrelor and on day 7 after switching clopidogrel to ticagrelor (day 8 of the in-hospital period). Results. Levels of CRP and IL-6 in the early period after STEMI in the groups of patients receiving clopidogrel and ticagrelor were similar (p=0.82 vs. p=0.27, respectively). On day 8, CRP levels in the clopidogrel group were significantly higher than CRP levels in the ticagrelor group on day 8 (25.3 (4.6; 46.4) ml / l vs. 17.5 (4.6; 20.9) mg / l, respectively (p = 0.04). The level of IL-6 in the clopidogrel group on day 8 was significantly higher than the level of IL-6 on day 8 in the ticagrelor group (7.03 (2.7; 11.3) pg / mL, vs. 2.8 (1.8; 4.2) pg / mL, respectively (p = 0.01). Conclusion. Levels of proinflammatory markers were significantly lower in the ticagrelor group on day 8 after STEMI compared to the clopidogrel group.
Highlights
80 patients with STEMI were included in the study
Plasma levels of IL-6 and clopidogrel or ticaC-reactive protein (CRP) were measured on day 1 after the hospital admis sion before replacing clopidogrel to ticagrelor and on day 7 after switching clopidogrel to ticagrelor
On day 8, CRP levels in the clopidogrel group were significantly higher than CRP levels in the ticagrelor group on day 8 (25.3 (4.6; 46.4) ml / l vs. 17.5 (4.6; 20.9) mg / l, respectively (p = 0.04)
Summary
Пациенты первой группы получали поддерживающую дозу клопидогрела 75 мг в сутки. Пациенты второй группы получали поддерживающую дозу тикагрелора 90 мг 2 раза в сутки. При исследовании уровня СРБ и ИЛ-6 в первые сутки от развития HMnST значимых различий в группах клопидогрела и тикагрелора выявлено не было (р=0,82 и р=0,27, соответственно). Уровень СРБ на 8-е сутки развития MMnST в группе клопидогрела был достоверно выше по сравнению с группой тикагрелора: 25,3 (4,6; 46,4) мл/л и 17,5 (4,6; 20,9) мг/л соответственно (р=0,04). В группе клопидогрела на 8-е сутки течения MMnST уровень ИЛ-6 достоверно был выше по сравнению с группой тикагрелора: 7,03 (2,7; 11,3) пг/мл и 2,8 (1,8; 4,2) пг/мл, соответственно (р=0,01). Уровень провоспалительных мар керов в группе тикагрелора на восьмые сутки развития MMnST достоверно ниже, чем в группе пациентов, продолжающих принимать клопидогрел. Алексеенко А.В., Учасова Е.Г., Груздева О.В., Барбараш О.Л.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
